Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Nov
22
UCB Submits Response to FDA Complete Response Letter for Bimekizumab
Nov
14
UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients
Sep
26
UCB U.S. Headquarters in Atlanta Awarded Prestigious LEED Gold WELL Platinum Certifications
Sep
26
UCB Achieves Two Awards Recognizing our Sustainability Efforts for the Atlanta Warehouse Expansion
Sep
22
UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting
Aug
17
UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters
Aug
16
How Winners of the UCB Family Epilepsy Scholarship Prepare to Go Back to School
Jun
13
UCB Builds Partnerships with Rare Epilepsy Syndrome Patient Groups
Jun
06
UCB Hosts HRH Princess Astrid and Belgian Economic Mission at Atlanta Campus